Navigation Links
Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Date:12/1/2009

NEW YORK, Dec. 1 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

http://www.reportlinker.com/p0166814/The-Future-of-Central-Nervous-System-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html

Summary

The author has released its latest research "The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global CNS diseases therapeutics market. The report analyzes the markets for CNS disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the CNS diseases therapeutics market from 2000 to 2008, forecast forward to 2015

- Analysis of the leading therapeutic segments including Alzheimer's disease, Parkinson's disease, Schizophrenia and Bipolar Disorder, Epilepsy, Major depressive disorder (MDD), anxiety and panic disorder, Attention Deficit Hyperactivity Disorder (ADHD) and Insomnia.

- Analysis of the CNS diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the CNS diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Lundbeck A/S, AstraZeneca, Merck & Co, Pfizer Inc, UCB S.A., Bristol-Myers Squibb and Eli Lilly

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global CNS diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 9

1.2 List of Figures 15

2 Global CNS Therapeutics Market : Introduction 20

2.1 Disease Overview 20

2.2 GBI Research Report Guidance 20

3 Global CNS Therapeutics Market: Market Characterization 22

3.1 Market Overview 22

3.2 Market Forecasts 24

3.3 Branded Versus Generics 25

3.4 Market Share by Disease Sectors 26

3.5 Average Cost of Therapy 26

3.6 Volume 28

3.7 Usage Patterns 29

3.7.1 Diseased Population 29

3.7.2 Treatment Seeking Population 30

3.7.3 Diagnosis Population 31

3.7.4 Prescription Population 32

3.7.5 Therapeutic Usage Patterns 33

3.8 Geographical Distribution 34

3.9 Market Drivers and Restraints 36

3.9.1 Market Drivers 36

3.9.2 Market Restraints 37

3.10 Unmet Needs 39

3.10.1 Alzheimer's Disease 40

3.10.2 Parkinson's Disease 40

3.10.3 Schizophrenia and bipolar Disorder 40

3.10.4 Depression 40

3.10.5 Insomnia 40

3.11 Key Market Trends 41

3.11.1 Increase in Disease Incidence and Prevalence Rates 41

3.11.2 Product Pipeline 41

3.11.3 Advertising and Commercialization 42

3.11.4 Regulatory trends - Current Reimbursement Scenario 42

4 Global Alzheimer's Disease Therapeutics Market 44

4.1 Market Overview 44

4.2 Market Forecasts 44

4.3 Average Cost of Therapy 45

4.4 Volume 46

4.5 Usage Patterns 48

4.5.1 Diseased Population 48

4.5.2 Treatment Seeking Population 49

4.5.3 Diagnosis Population 50

4.5.4 Prescription Population 51

4.5.5 Therapeutic Usage Patterns 52

4.6 Product Analysis 53

4.6.1 Aricept 53

4.6.2 Exelon and Exelon Patch 54

4.6.3 Ebixa (Namenda) 55

4.6.4 Razadyne and Reminyl 55

4.7 Drug Pipeline Analysis 55

5 Global Parkinson's Disease Therapeutics Market 59

5.1 Market Overview 59

5.2 Market Forecasts 59

5.3 Average Cost of Therapy 61

5.4 Volume 62

5.5 Usage Patterns 63

5.5.1 Diseased Population 63

5.5.2 Treatment Seeking Population 64

5.5.3 Diagnosis Population 65

5.5.4 Prescription Population 66

5.5.5 Therapeutic Usage Patterns 67

5.6 Product Analysis 68

5.6.1 Azilect 68

5.6.2 Stalevo/Comtan 69

5.6.3 Madopar 69

5.6.4 Neupro 69

5.6.5 Requip/Requip XL 70

5.6.6 Sifrol/Mirapex 70

5.6.7 Sinemet 70

5.7 Drug Pipeline Analysis 70

6 Global Schizophrenia and Bipolar Disorder Therapeutics Market 73

6.1 Market Overview 73

6.2 Market Forecasts 73

6.3 Average Cost of Therapy 75

6.4 Volume 76

6.5 Usage Patterns 77

6.5.1 Diseased Population 77

6.5.2 Treatment Seeking Population 78

6.5.3 Diagnosis Population 79

6.5.4 Prescription Population 80

6.5.5 Therapeutic Usage Patterns 81

6.6 Product Analysis 82

6.6.1 Abilify 82

6.6.2 Clozaril 83

6.6.3 Geodon/Zeldox 83

6.6.4 Invega 84

6.6.5 Risperdal/Risperdal Consta 85

6.6.6 Serdolect 85

6.6.7 Seroquel 85

6.6.8 Zyprexa 86

6.7 Drug Pipeline Analysis 86

7 Global Epilepsy Therapeutics Market 89

7.1 Market Overview 89

7.2 Market Forecasts 89

7.3 Average Cost of Therapy 90

7.4 Volume 91

7.5 Usage Patterns 92

7.5.1 Diseased Population 92

7.5.2 Treatment Seeking Population 93

7.5.3 Diagnosis Population 94

7.5.4 Prescription Population 95

7.5.5 Therapeutic Usage Patterns 96

7.6 Product Analysis 98

7.6.1 Depakine 98

7.6.2 Keppra/Keppra XR and Vimpat 98

7.6.3 Lamictal 99

7.6.4 Lyrica 100

7.6.5 Neurontin 100

7.6.6 Tegretol 100

7.6.7 Trileptal 100

7.6.8 Topamax 101

7.6.9 Vimpat 101

7.7 Drug Pipeline Analysis 101

8 Global MDD, Anxiety and Panic Disorder Therapeutics Market 103

8.1 Market Overview 103

8.2 Market Forecasts 103

8.3 Average Cost of Therapy 105

8.4 Volume 106

8.5 Usage Patterns 107

8.5.1 Diseased Population 107

8.5.2 Treatment Seeking Population 108

8.5.3 Diagnosis Population 109

8.5.4 Prescription Population 110

8.5.5 Therapeutic Usage Patterns 111

8.6 Product Analysis 112

8.6.1 Celexa 112

8.6.2 Cipralex 113

8.6.3 Cymbalta 113

8.6.4 Effexor 114

8.6.5 Lexapro 114

8.6.6 Pristiq 114

8.6.7 Seroxat/Paxil 114

8.6.8 Wellbutrin/Wellbutrin XL 115

8.6.9 Xanax 115

8.6.10 Zoloft 115

8.7 Drug Pipeline Analysis 115

9 Global ADHD Therapeutics Market 118

9.1 Market Overview 118

9.2 Market Forecasts 118

9.3 Average Cost of Therapy 120

9.4 Volume 121

9.5 Usage Patterns 121

9.5.1 Diseased Population 121

9.5.2 Treatment Seeking Population 122

9.5.3 Diagnosis Population 123

9.5.4 Prescription Population 124

9.5.5 Therapeutic Usage Patterns 125

9.6 Product Analysis 127

9.6.1 Adderall/Adderall XR 127

9.6.2 Concerta 127

9.6.3 Daytrana 127

9.6.4 Focalin/Retalin 128

9.6.5 Strattera 129

9.6.6 Vyvanse 129

9.7 Drug Pipeline Analysis 129

10 Global Insomnia Therapeutics Market 131

10.1 Market Overview 131

10.2 Market Forecasts 131

10.3 Average Cost of Therapy 133

10.4 Volume 134

10.5 Usage Patterns 135

10.5.1 Diseased Population 135

10.5.2 Treatment Seeking Population 136

10.5.3 Diagnosis Population 137

10.5.4 Prescription Population 138

10.5.5 Therapeutic Usage Patterns 138

10.6 Product Analysis 140

10.6.1 Halcion 140

10.6.2 Lunesta 140

10.6.3 Rozerem 141

10.6.4 Ambien/Stilnox/Ambien CR 141

10.6.5 Sonata 142

10.7 Drug Pipeline Analysis 142

11 Global CNS Therapeutics Market: The US Market 146

11.1 Market Overview 146

11.2 Market Forecasts 146

11.3 Average Cost of Therapy 148

11.4 Volume 149

11.5 Usage Patterns 149

11.5.1 Diseased Population 149

11.5.2 Treatment Seeking Population 151

11.5.3 Diagnosis Population 152

11.5.4 Prescription Population 153

11.5.5 Therapeutic Usage Patterns 154

12 Global CNS Therapeutics Market: The European Market 156

12.1 Market Overview 156

12.2 Market Forecasts 156

12.3 Average Cost of Therapy 157

12.4 Volume 158

12.5 Usage Patterns 159

12.5.1 Diseased Population 159

12.5.2 Treatment Seeking Population 160

12.5.3 Diagnosis Population 161

12.5.4 Prescription Population 162

12.5.5 Therapeutic Usage Patterns 163

13 Global CNS Therapeutics Market: The Japanese Market 165

13.1 Market Overview 165

13.2 Market Forecasts 165

13.3 Average Cost of Therapy 166

13.4 Volume 168

13.5 Usage Patterns 168

13.5.1 Diseased Population 168

13.5.2 Treatment Seeking Population 170

13.5.3 Diagnosis Population 170

13.5.4 Prescription Population 171

13.5.5 Therapeutic Usage Patterns 172

14 Global CNS Therapeutics Market: Competitive Landscape 175

14.1 Overview 175

14.2 Market Share Analysis 176

14.3 Competitive Profiling 178

14.3.1 AstraZeneca 179

14.3.2 Boehringer Ingelheim 179

14.3.3 Bristol-Myers Squibb 179

14.3.4 Eli Lilly 179

14.3.5 GlaxoSmithKline (GSK) 179

14.3.6 Johnson & Johnson 180

14.3.7 H. Lundbeck A/S 180

14.3.8 Novartis 180

14.3.9 Pfizer 181

14.3.10 Sanofi Aventis 181

14.3.11 Shire Pharmaceuticals 181

14.3.12 UCB Pharma 181

14.3.13 Wyeth 181

15 Global CNS Therapeutics Market: Strategic Consolidations 183

15.1 Mergers and Acquisitions 183

15.1.1 Overview 183

15.2 Licensing Agreements 185

15.2.1 Preclinical 187

15.2.2 Phase I 188

15.2.3 Phase II 189

15.2.4 Phase III 190

15.2.5 Approved 191

16 Global CNS Therapeutics Market : Appendix 193

16.1 Market Definitions 193

16.2 Abbreviations 193

16.3 Research Methodology 193

16.4 Coverage 194

16.5 Secondary Research 194

16.6 Primary Research 195

16.7 Models 195

16.8 Forecasts 195

16.8.1 Epidemiology-based Forecasting 195

16.9 Expert Panel Validation 197

16.10 Contact Us 198

16.11 Disclaimer 198

1.1 List of Tables

Table 1: CNS Therapeutics Market, Global, Revenues ($m), 2000-2008 24

Table 2: CNS Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 24

Table 3: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008 25

Table 4: CNS Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015 26

Table 5: CNS Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 27

Table 6: CNS Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($),

2008-2015 27

Table 7: CNS Therapeutics Market, Global, Historical Figures for Volume (000), 2000-2008 28

Table 8: CNS Therapeutics Market, Global, Forecasts for Volume, 2008-2015 28

Table 9: CNS Therapeutics Market, Global, Historical Figures for Diseased Population,

2000-2008 29

Table 10: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 29

Table 11: CNS Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 30

Table 12: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 30

Table 13: CNS Therapeutics Market, Global, Historical Figures for Diagnosis Population,

2000-2008 31

Table 14: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 31

Table 15: CNS Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 32

Table 16: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 32

Table 17: CNS Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 33

Table 18: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns,

2008-2015 34

Table 19: CNS Therapeutics Market, Global, Market Drivers, 2008 36

Table 20: CNS Therapeutics Market, Global, Market Restraints, 2008 37

Table 21: CNS Therapeutics Market, Global, Major Drug Patent Expirations, 2008-2015 38

Table 22: CNS Therapeutics Market, Global, Reimbursement Policies of Various 43

Table 23: Alzheimer's Disease Therapeutics Market, Historical Revenue ($m), 2000-2008 45

Table 24: Alzheimer's Disease Therapeutics Market, Revenue Forecasts ($m), 2008-2015 45

Table 25: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 46

Table 26: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 46

Table 27: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 47

Table 28: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Volume, 2008-2015 47

Table 29: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 48

Table 30: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 49

Table 31: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 49

Table 32: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 50

Table 33: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 50

Table 34: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 51

Table 35: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 51

Table 36: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 52

Table 37: Alzheimer's Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 53

Table 38: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 53

Table 39: Alzheimer's Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 53

Table 40: Alzheimer's Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008 56

Table 41: Parkinson's Disease Therapeutics Market, Global, Historical Revenues ($m),

2000-2008 60

Table 42: Parkinson's Disease Therapeutics Market, Global, Revenue Forecasts ($m),

2008-2015 61

Table 43: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 61

Table 44: Parkinson's Disease Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 62

Table 45: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 62

Table 46: Parkinson's Disease Therapeutics Market, Global, Forecasts for Volume, 2008-2015 63

Table 47: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 64

Table 48: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 64

Table 49: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 65

Table 50: Parkinson's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 65

Table 51: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 66

Table 52: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 66

Table 53: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 67

Table 54: Parkinson's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 67

Table 55: Parkinson's Disease Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 68

Table 56: Parkinson's Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 68

Table 57: Parkinson's Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 68

Table 58: Parkinson's Disease Therapeutics Market, Global, Clinical Trials Pipeline, 2008 71

Table 59: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 74

Table 60: Schizophrenia and Bipolar Disorder Therapeutics Market, Global,, Revenue Forecasts ($m), 2008-2015 75

Table 61: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 76

Table 62: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 76

Table 63: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 77

Table 64: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015 77

Table 65: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 78

Table 66: Schizophrenia and Bipolar Disorder Therapeutics Market, Forecasts for Diseased Population, 2008-2015 78

Table 67: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 79

Table 68: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 79

Table 69: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 80

Table 70: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 80

Table 71: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 81

Table 72: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 81

Table 73: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 82

Table 74: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 82

Table 75: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 83

Table 76: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 86

Table 77: Epilepsy Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 90

Table 78: Epilepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 90

Table 79: Epilepsy Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 91

Table 80: Epilepsy Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 91

Table 81: Epilepsy Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 92

Table 82: Epilepsy Therapeutics Market, Global, Forecasts for Volume, 2008-2015 92

Table 83: Epilepsy Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 93

Table 84: Epilepsy Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 93

Table 85: Epilepsy Therapeutics Market, Global, Historical Figures for Treatment Seeking Population, 2000-2008 94

Table 86: Epilepsy Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 94

Table 87: Epilepsy Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 95

Table 88: Epilepsy Therapeutics Market, Global, Forecasts for Diagnosis Population,

2008-2015 95

Table 89: Epilepsy Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 96

Table 90: Epilepsy Therapeutics Market, Forecasts for Prescription Population, 2008-2015 96

Table 91: Epilepsy Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patters, 2000-2008 97

Table 92: Epilepsy Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 97

Table 93: Epilepsy Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 98

Table 94: Epilepsy Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 101

Table 95: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Revenues ($m), 2000-2008 104

Table 96: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2008-2015 104

Table 97: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Average Cost of Therapy ($), 2000-2008 105

Table 98: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Average Cost of Therapy ($), 2008-2015 105

Table 99: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Volume, 2000-2008 106

Table 100: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Volume, 2008-2015 106

Table 101: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diseased Population, 2000-2008 107

Table 102: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2008-2015 108

Table 103: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historic Figures for Treatment Seeking Population, 2000-2008 108

Table 104: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2008-2015 109

Table 105: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Diagnosis Population, 2000-2008 109

Table 106: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Diagnosis Population, 2008-2015 110

Table 107: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Prescription Population, 2000-2008 110

Table 108: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Forecasts for Prescription Population, 2008-2015 111

Table 109: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Historical Figures for Therapeutic Usage Patterns, 2000-2008 112

Table 110: MDD, Anxiety Panic Disorder Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2008-2015 112

Table 111: MDD, Anxiety and Panic Disorder Therapeutics Market, Global, Major Manufacturers and Drugs, 2008 112

Table 112: Global MDD, Panic and Anxiety Disorder Therapeutics Market, Clinical Trials Drug Portfolio, 2008 115

Table 113: Global ADHD Therapeutics Market, Historical Revenues ($m), 2000-2008 119

Table 114: Global ADHD Therapeutics Market, Revenues Forecasts ($million), 2008-2015 119

Table 115: ADHD Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008 120

Table 116: ADHD Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 120

Table 117: Global ADHD Therapeutics Market, Historical Figures for Volume, 2000-2008 121

Table 118: Global ADHD Therapeutics Market, Forecasts for Volume, 2008-2015 121

Table 119: Global ADHD Therapeutics Market, Historical Figures for Diseased Population,

2000-2008 122

Table 120: Global ADHD Therapeutics Market, Forecasts for Diseased Population, 2008-2015 122

Table 121: Global ADHD Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008 123

Table 122: Global ADHD Therapeutics Market, Forecasts for Treatment Seeking Population, 2008-2015 123

Table 123: Global ADHD Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008 124

Table 124: Global ADHD Therapeutics Market, Forecasts for Diagnosis Population, 2008-2015 124

Table 125: Global ADHD Therapeutics Market, Historical Figures for Prescription Population, 2000-2008 125

Table 126: Global ADHD Therapeutics Market, Forecasts for Prescription Population,

2008-2015 125

Table 127: Global ADHD Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008 126

Table 128: Global ADHD Therapeutics Market, Forecasts for Therapeutic Usage Patterns,

2008-2015 126

Table 129: Global ADHD Therapeutics Market, Major Manufacturers and Drugs, 2008 127

Table 130: Global Insomnia Therapeutics Market, Historical Revenues ($m), 2000-2008 132

Table 131: Global Insomnia Therapeutics Market, Revenue Forecasts ($m), 2008-2015 132

Table 132: Global Insomnia Therapeutics Market, Historical Figures for Average Cost of Therapy ($), 2000-2008 133

Table 133: Global Insomnia Therapeutics Market, Forecasts for Average Cost of Therapy ($), 2008-2015 133

Table 134: Insomnia Therapeutics Market, Historical Figures for Volume, 2000-2008 134

Table 135: Insomnia Therapeutics Market, Forecasts for Volume, 2008-2015 134

Table 136: Global Insomnia Therapeutics Market, Historical Figures for Diseased Population, 2000-2008 135

Table 137: Global Insomnia Therapeutics Market, Forecasts for Diseased Population,

2008-2015 135

Table 138: Global Insomnia Therapeutics Market, Historical Figures for Treatment Seeking Population, 2000-2008 136

Table 139: Insomnia Therapeutics Market, Forecasts for Treatment Seeking Population,

2008-2015 136

Table 140: Global Insomnia Therapeutics Market, Historical Figures for Diagnosis Population, 2000-2008 137

Table 141: Global Insomnia Therapeutics Market, Forecasts for Diagnosis Population,

2008-2015 137

Table 142: Global Insomnia Therapeutics Market, Historical Figures for Prescription Population, 2000-2008 138

Table 143: Global Insomnia Therapeutics Market, Forecasts for Prescription Population,

2008-2015 138

Table 144: Global Insomnia Therapeutics Market, Historical Figures for Therapeutic Usage Patterns, 2000-2008 139

Table 145: Global Insomnia Therapeutics Market, Forecasts for Therapeutic Usage Patterns, 2008-2015 139

Table 146: Global Insomnia Therapeutics Market, Major Manufacturers and Drugs, 2008 140

Table 147: Insomnia Therapeutics Market, Clinical Trials Pipeline, 2008 142

Table 148: CNS Therapeutics Market, US, Historical Revenues ($m), 2000-2008 147

Table 149: CNS Therapeutics Market, US, Revenue Forecasts ($m), 2008-2015 147

Table 150: CNS Therapeutics Market, US, Historical Figures for the Average Cost of Therapy ($), 2000-2008 148

Table 151: CNS Therapeutics Market, US, Forecasts for the Average Cost of Therapy ($),

2008-2015 148

Table 152: CNS Therapeutics Market, US, Historical Figures for Volume, 2000-2008 149

Table 153: CNS Therapeutics Market, US, Forecasts for Volume, 2008-2015 149

Table 154: CNS Therapeutics Market, US, Historical Figures for Diseased Population,

2000-2008 150

Table 155: CNS Therapeutics Market, US, Forecasts for Diseased Population, 2008-2015 151

Table 156: CNS Therapeutics Market, US, Historical Figures for Treatment Seeking Population, 2000-2008 151

Table 157: CNS Therapeutics Market, US, Forecasts for Treatment Seeking Population,

2008-2015 152

Table 158: CNS Therapeutics Market, US, Historical Figures for Diagnosis Population,

2000-2008 153

Table 159: CNS Therapeutics Market, US, Forecasts for Diagnosis Population, 2008-2015 153

Table 160: CNS Therapeutics Market, US, Historical Figures for Prescription Population,

2000-2008 154

Table 161: CNS Therapeutics Market, US, Forecasts for Prescription Population, 2008-2015 154

Table 162: CNS Therapeutics Market, US, Historical Figures for Usage Patterns, 2000-2008 155

Table 163: CNS Therapeutics Market, US, Forecasts for Usage Patterns, 2008-2015 155

Table 164: CNS Therapeutics Market, Europe, Historical Revenues ($m), 2000-2008 157

Table 165: CNS Therapeutics Market, Europe, Revenue Forecasts ($m), 2008-2015 157

Table 166: CNS Therapeutics Market, Europe, Historical Figures for Average Cost of Treatment, 2000-2008 158

Table 167: CNS Therapeutics Market, Europe, Forecasts for Average Cost of Treatment,

2008-2015 158

Table 168: CNS Therapeutics Market, Europe, Historical Figures for Volume, 2000-2008 159

Table 169: CNS Therapeutics Market, Europe, Forecasts for Volume, 2008-2015 159

Table 170: CNS Therapeutics Market, Europe, Historical Figures for Diseased Population,

2000-2008 160

Table 171: CNS Therapeutics Market, Europe, Forecasts for Diseased Population, 2008-2015 160

Table 172: CNS Therapeutics Market, Europe, Historical Figures for Treatment Seeking Population, 2000-2008 161

Table 173: CNS Therapeutics Market, Europe, Forecasts for Treatment Seeking Population, 2008-2015 161

Table 174: CNS Therapeutics Market, Europe, Historical Figures for Diagnosis Population, 2000-2008 162

Table 175: CNS Therapeutics Market, Europe, Forecasts for Diagnosis Population, 2008-2015 162

Table 176: CNS Therapeutics Market, Europe, Historical Figures for Prescription Population, 2000-2008 163

Table 177: CNS Therapeutics Market, Europe, Forecasts for Prescription Population, 2008-2015 163

Table 178: CNS Therapeutics Market, Europe, Historical Figures for Therapeutic Usage Patterns, 2000-2008 164

Table 179: CNS Therapeutics Market, Europe, Forecasts for Therapeutic Usage Patterns,

2008-2015 164

Table 180: CNS Therapeutics Market, Japan, Historical Revenues ($m), 2000-2008 166

Table 181: CNS Therapeutics Market, Japan, Revenue Forecasts ($m), 2008-2015 166

Table 182: CNS Therapeutics Market, Japan, Historical Figures for Average Cost of Therapy ($), 2000-2008 167

Table 183: CNS Therapeutics Market, Japan, Forecasts for Average Cost of Therapy ($),

2008-2015 167

Table 184: CNS Therapeutics Market, Japan, Historical Figures for Volume, 2000-2008 168

Table 185: CNS Therapeutics Market, Japan, Forecasts for Volume, 2008-2015 168

Table 186: CNS Therapeutics Market, Japan, Historical Figures for Diseased Population,

2000-2008 169

Table 187: CNS Therapeutics Market, Japan, Forecasts for Diseased Population, 2008-2015 169

Table 188: CNS Therapeutics Market, Japan, Historical Figures for Treatment Seeking Population, 2000-2008 170

Table 189: CNS Therapeutics Market, Japan, Forecasts for Treatment Seeking Population, 2008-2015 170

Table 190: CNS Therapeutics Market, Japan, Historical Figures for Diagnosis Population,

2000-2008 171

Table 191: CNS Therapeutics Market, Japan, Forecasts for Diagnosis Population, 2008-2015 171

Table 192: CNS Therapeutics Market, Japan, Historical Figures for Prescription Population, 2000-2008 172

Table 193: CNS Therapeutics Market, Japan, Forecasts for Prescription Population, 2008-2015 172

Table 194: CNS Therapeutics Market, Japan, Historical Figures for Therapeutic Usage Patterns, 2000-2008 173

Table 195: CNS Therapeutics Market, Japan, Forecasts for Therapeutic Usage Patterns,

2008-2015 174

Table 196: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008 187

Table 197: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2008 188

Table 198: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2008 189

Table 199: CNS Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2008 190

Table 200: CNS Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008 191

1.2 List of Figures

Figure 1: CNS Therapeutics Market, Global, Market Overview, 2008 22

Figure 2: CNS Therapeutics Market, Global, Key Geographical Trends, 2008 23

Figure 3: CNS Therapeutics Market, Global, Revenue Forecasts ($bn), 2000-2015 24

Figure 4: CNS Therapeutics Market, Global, Revenue Split ($bn), 2000-2015 25

Figure 5: CNS Therapeutics Market, Global, Market Share of Major Disease Sectors, 2008 26

Figure 6: Global CNS Therapeutics Market, Average Cost of Therapy ($), 2000-2015 27

Figure 7: CNS Therapeutics Market, Global, Forecasts for Volume, 2000-2015 28

Figure 8: CNS Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 29

Figure 9: CNS Therapeutics Market, Global, Forecasts for Treatment Seeking Population,

2000-2015 30

Figure 10: CNS Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 31

Figure 11: CNS Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 32

Figure 12: CNS Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns,

2000-2015 33

Figure 13: CNS Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2000-2015 34

Figure 14: CNS Therapeutics Market, Global, Geographical Comparison of Market Competition, 2008 35

Figure 15: CNS Therapeutics Market, Global, Market Indicators, 2008 36

Figure 16: CNS Therapeutics Market, Global, Analysis of Unmet Needs for Major Disease Sectors, 2008 39

Figure 17: CNS Therapeutics Market, Global, Key Market Events, 2008-2015 41

Figure 18: Alzheimer's Disease Therapeutics Market, Global, Revenue Forecasts ($m),

2000-2015 44

Figure 19: Alzheimer's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 46

Figure 20: Alzheimer's Disease Therapeutics Market, Global, Global, Forecasts for Volume, 2000-2015 47

Figure 21: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 48

Figure 22: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 49

Figure 23: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 50

Figure 24: Alzheimer's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 51

Figure 25: Alzheimer's Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 52

Figure 26: Alzheimer's Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008 54

Figure 27: Alzheimer's Disease Therapeutics Market, Global, Historical Revenues of Major Drugs ($m), 2006-2008 55

Figure 28: Alzheimer's Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Clinical Development, 2008 57

Figure 29: Alzheimer's Disease Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 57

Figure 30: Alzheimer's Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 58

Figure 31: Parkinson's Disease Therapeutics Market, Global, Revenue Forecasts ($m),

2000-2015 60

Figure 32: Parkinson's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 61

Figure 33: Parkinson's Disease Therapeutics Market, Global, Forecasts for Volume, 2000-2015 62

Figure 34: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 63

Figure 35: Parkinson's Disease Therapeutics Market, Global, Forecasts for Treatment Seeking Population, 2000-2015 64

Figure 36: Parkinson's Disease Therapeutics Market, Global, Forecasts for Diagnosis Population, 2000-2015 65

Figure 37: Parkinson's Disease Therapeutics Market, Global, Forecasts for Prescription Population, 2000-2015 66

Figure 38: Parkinson's Disease Therapeutics Market, Global, Forecasts for Therapeutic Usage Patterns, 2000-2015 67

Figure 39: Parkinson's Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008 69

Figure 40: Parkinson's Disease Therapeutics Market, Global, Historic Revenues of Major Drugs ($m), 2006-2008 70

Figure 41: Parkinson's Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008 71

Figure 42: Parkinson's Disease Therapeutics Market, Global, Clinical Trials Drug Portfolio, 2008 72

Figure 43: Parkinson's Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008 72

Figure 44: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Revenue Forecasts ($m), 2000-2015 74

Figure 45: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015 75

Figure 46: Schizophrenia and Bipolar Disorder Therapeutics Markets, Global, Forecasts for Volume, 2000-2015 76

Figure 47: Schizophrenia and Bipolar Disorder Therapeutics Market, Global, Forecasts for Diseased Population, 2000-2015 77

Figure 48: Schizophrenia and Bipolar Disorder Therapeutics Market, Glob

To order this report:

Therapy Industry: The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment
2. Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds Peptic Ulcer Testing - A World Market Intelligence Report
4. Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
5. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
6. Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities
7. Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition)
8. Reportlinker Adds Childrens Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition
9. Reportlinker Adds Hand Sanitizers - US Market Trends
10. Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
11. Reportlinker Adds Imaging Agents - A Worldwide Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: